![]() ![]() ![]() (“Checkmate”), and actual events or results may differ materially from these forward-looking statements. (“Regeneron”) and Checkmate Pharmaceuticals, Inc. This communication includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. on April 20, 2022).ĮX-99.4 - Announcements by Checkmate and Checkmate’s management via Twitter on Ap(incorporated herein by reference to Exhibit 99.4 to the Schedule 14D-9C filed by Checkmate Pharmaceuticals, Inc. on April 20, 2022).ĮX-99.3 - Announcements by Checkmate and Checkmate’s management via LinkedIn on Ap(incorporated herein by reference to Exhibit 99.3 to the Schedule 14D-9C filed by Checkmate Pharmaceuticals, Inc. on April 20, 2022).ĮX-99.2 - Email from Alan Bash, Chief Executive Officer of Checkmate to commercial partners on Ap(incorporated herein by reference to Exhibit 99.2 to the Schedule 14D-9C filed by Checkmate Pharmaceuticals, Inc. (Name of SubjectĮX-99.1 - Email from Alan Bash, Chief Executive Officer of Checkmate to employees on Ap(incorporated herein by reference to Exhibit 99.1 to the Schedule 14D-9C filed by Checkmate Pharmaceuticals, Inc. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Checkmate Pharmaceuticals, Inc. SC14D9C - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |